VH4524184
Sponsors
ViiV Healthcare
Conditions
HIV Infections
Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity
CompletedNCT05631704
Start: 2022-12-02End: 2023-07-27Updated: 2025-12-29
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
CompletedNCT06310616
Start: 2024-03-06End: 2024-08-15Updated: 2024-12-10
A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults
CompletedNCT07066722
Start: 2025-07-07End: 2025-12-17Updated: 2026-03-09
Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
RecruitingNCT07636928
Start: 2026-06-04End: 2026-08-20Target: 9Updated: 2026-07-02
Phase 2
VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1
CompletedNCT06214052
Start: 2024-02-07End: 2024-06-12Updated: 2025-06-29
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RecruitingNCT07202546
Start: 2026-02-11End: 2028-07-24Target: 150Updated: 2026-05-08